Command Palette

Search for a command to run...

ZOTA

1377.1-5.54%
Market Cap
₹4,481.55 Cr
Stock P/E
-77.28
ROCE
-28.07%
ROE
-36.18%
Book Value
₹116.40

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

POSITIVES
  • Strong revenue growth with a high-quality contribution from DavaIndia.
  • DavaIndia remains the largest revenue contributor and grew sharply.
NEGATIVES
  • Store closures indicate shuttering of underperformers; potential scalability risk.
  • Near-term profitability depends on store maturation; transition to profitability may take time.

Peers Summary

Sector Leader

Zota Health Care Ltd. shows poor profitability and high levels of debt compared to its peers in the Pharmaceuticals & Drugs industry. However, its strong revenue growth indicates potential. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. stand out as strong performers, exhibiting solid profitability and reasonable valuations.

Key Points
  • Zota Health Care has the highest revenue growth YoY (28.96%) but the lowest profitability metrics (negative ROE and EPS).
  • Cipla Ltd. and Dr. Reddy's Laboratories Ltd. are the most profitable peers with robust margins and returns, along with attractive valuations.
  • Sun Pharmaceutical Industries Ltd. and Divi's Laboratories Ltd. appear overvalued relative to their growth and profitability metrics.
Top Performers
Cipla Ltd.

Strong profitability metrics with a ROE of 16.63% and low valuation (PE of 23.73).

Dr. Reddy's Laboratories Ltd.

Robust profitability with a ROE of 21.76% and a low PE ratio of 15.50.

Mankind Pharma Ltd.

High revenue growth and strong profitability metrics, though slightly higher valuation.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.